Threats to the Neuronal Genome - An IOA & PCGI Symposium
On April 9, 2024 the Institute on Aging (IOA) and Penn Center for Genome Integrity (PCGI) co-hosted a symposium titled "Threats to the Neuronal Genome."
The IOA and PCGI share missions to bring basic, translational, and clinical researchers together and in recognition of this mission and the role of genome maintenance in neurodegenerative disease, the symposium covered several related topics including neuronal DNA damage and neuronal somatic variants. The full-day symposium featured keynotes by Drs. Michael B. Miller, Li-Huei Tsai, and Andre Nussenzweig, with trainee talks as well as a poster session.
The Science of Aging: An IOA Newsletter, Spring 2024 Edition | DIGITAL VERSION
When conducting a clinical trial, investigators have ethical obligations throughout the entire course of the study, including the post-trial period. Some obligations may be more obvious during the pre-trial and trial periods, but the post-trial period is more of a “black box†with unseen inner workings, explained Emily Largent, PhD, RN, Emanuel and Robert Hart Assistant Professor of Medical Ethics & Health Policy at Penn Medicine, during a presentation at the IOA's 
Virginia Lee, PhD, and the late John Q. Trojanowski, MD, PhD, partners in life and in science, have long been recognized as trailblazers in the field of neurodegenerative disease research. Now, their legacy will be immortalized in the halls of the University of Pennsylvania, as they join the list of leaders at Penn who have been celebrated with portraits to honor their impacts and contributions not only to the university, but to their respective fields.